Organisation paid for research Program year 2025 Source: CMS Open Payments

Institute for the Advancement

Neither a doctor nor a teaching hospital

Research payments

$1,695,982

200 payments

Through program year 2025, Institute for the Advancement is reported as receiving $1,695,982 in research payments, across 200 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$60,336	25
2024	Research	$19,864	10
2023	Research	$625,957	98
2022	Research	$176,557	30
2021	Research	$811,530	35
2020	Research	$1,738	2

Breakdown

Who paid Research payments · program years 2020–2025

Bavarian Nordic A/S $818,913 133 payments
Becton, Dickinson and Company $665,451 2 payments
Abbott Laboratories $133,482 33 payments
Moderna TX, Inc. $48,593 19 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $14,296 1 payment
Genentech, Inc. $12,835 9 payments
GlaxoSmithKline, LLC. $2,412 3 payments

Studies the money was for Research payments · program years 2020–2025

Veritor Antigen Assay $665,451 2 payments
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $496,348 62 payments
Nct05238025 $156,909 25 payments
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $148,381 43 payments
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol $133,482 33 payments
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $47,743 18 payments
Nct05329220 $17,275 3 payments
BI 767551 EX 14870 Ph III in SARS Cov 2 Preventi $14,296 1 payment
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough $5,968 4 payments
PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $5,775 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.